CN1383379A - 皮脂溢性皮炎的治疗方法 - Google Patents
皮脂溢性皮炎的治疗方法 Download PDFInfo
- Publication number
- CN1383379A CN1383379A CN01801857A CN01801857A CN1383379A CN 1383379 A CN1383379 A CN 1383379A CN 01801857 A CN01801857 A CN 01801857A CN 01801857 A CN01801857 A CN 01801857A CN 1383379 A CN1383379 A CN 1383379A
- Authority
- CN
- China
- Prior art keywords
- ivermectin
- cream
- smear
- lotion
- seborrheic dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
皮脂溢性皮炎的治疗方法包括涂抹洗剂或霜剂形式的混合物,该混合物在洗剂的情况下包括治疗有效量伊维菌素的水溶液,浓度约为750微克每毫升(mcg/ml),如果用作霜剂,还包括药学上可接受的载体。每晚涂抹这样一种洗剂或霜剂持续七天,然后在维持的基础上每月使用一至四次。
Description
发明背景
皮脂溢性皮炎已知也称皮脂溢性湿疹和皮脂溢,是一种皮肤的慢性浅表性炎症疾病,能够影响身体的很多部位,包括头皮、眉毛、鼻唇褶痕、唇、耳、胸骨区、腋窝、乳腺下褶、脐、腹股沟和臀肌褶痕。该疾病是以很多形状、大小和表面纹理为特征的,经常是痂样的、微黄色的和伴有瘙痒的。它还是以缓解和加重为特征的。
皮脂溢性皮炎的病因学、发病机理和组织学是悬而未决的。不过,它在临床上很类似牛皮癣,很多研究人员相信这两种疾病共享一种有关的病因学,尽管牛皮癣是一种定义范围可宽可窄的疾病。其中,牛皮癣通常区别于皮脂溢性皮炎的是它不存在瘙痒,对化合物治疗有耐药性,例如硫化硒和pyrithonate锌,它们已经用于皮脂溢性疾病的治疗。
有些研究人员把皮脂溢性皮炎归因于锌缺乏,而其他人认为它的病因学在微生物方面。另有其他人相信存在激素的影响,因为该疾病不会出现在***之前。也有假说认为,有一种特殊的真菌引起各种形式的皮脂溢性皮炎,即lipophiolic plemorphic。照此,被视为有说服力的一种论点是酵母是这类皮炎的至少一种原因,它是这类真菌的普通形式。
反映皮脂溢性皮炎是锌缺乏这一观点的现有技术是Akiko等的美国专利No.5,997,852(1999),发明名称为皮炎药物,而认为皮脂溢性皮炎起因于微生物并由此主张用抗生素治疗的学说反映在Rosenberg等的美国专利No.4,965,935(1986)中,发明名称为用咪唑抗生素局部治疗牛皮癣。照此,Rosenberg等把病原性牛皮癣与病原性皮脂溢性皮炎视为等同。有鉴于这种状况,也常采用polymycin B-氢化可的松,即一种含有可的松的抗生素作为局部药液。
本发明得自认为皮脂溢性皮炎本质上由真菌引起的学说,照此,是由微观生物谱中最大端的生物所导致的。也就是大于细菌但仍然是人眼不可见的生物。它们包括尚未检测到的微生物,对局部伊维菌素治疗敏感或有应答。
发明概述
本发明构建了皮脂溢性皮炎的治疗方法,由涂抹一种洗剂或霜剂形式的混合物组成,在洗剂的情况下,该混合物包含治疗有效量的伊维菌素水溶液,该水溶液浓度为约750微克每毫升(mcg/ml),如果用作霜剂,则包含药学上可接受的载体。每晚涂抹这样一种洗剂或霜剂持续七天,然后在维持的基础上每月使用一至四次。
因此,本发明的一个目的是提供有效治疗皮脂溢性皮炎的局部疗法。
另一个目的是提供安全有效治疗这类皮炎的方法,该方法从此将提供基本上永久的减轻效果。
下列发明的详细说明和随附的权利要求书将使本发明的上述和其他目的和优点变得显而易见。发明的详细说明
伊维菌素是已知为1 3-脱氧糖苷配基的一大类化学品中的一部分,本发明关于它的局部用途在历史上已经成为Merck & Co.,Inc.,Rahway,New Jersey的一种产品。它在历史上用于兽医应用,用于治疗动物的内寄生物性疾病。不过,有些医学文章、特别是来自于第三世界和热带地区的医学文章已经提示了伊维菌素在人内部或内寄生物性疾病治疗中的局部用途,例如蝇蛆病和盘尾丝虫病。不过,这些疾病与皮脂溢性皮炎、或者就此而言与任何已知形式的牛皮癣之间不存在已知的病原性或组织学联系。进而,就发明人所知,没有文献曾经提示过伊维菌素在治疗任何形式的皮炎中的局部应用。
本发明涉及治疗有效量伊维菌素的用途,一般可从Merck获得它的糊剂,当溶于水时,其足以形成浓度至少为750mcg/ml的洗剂。或者,可以形成伊维菌素的霜剂,将其与药学上可接受的载体结合,例如丙二醇、月桂基硫酸钠、黄原胶或其组合。
然后在病变部位上每日涂抹洗剂或霜剂持续七天,此后每月一至四次,以预防疾病的复发。
关于作用机理,据信伊维菌素对皮肤的作用主要涉及皮脂腺,后者存在于人皮肤的几乎每个滤泡内,易受真菌攻击。因此,在这点上适用皮脂溢性皮炎的真菌理论以及激素机能障碍理论。而且,由于已经证明伊维菌素用药对皮肤具有松弛作用,也适用与情绪应激反应及相关的出汗增加有关的病因学理论,这些反应是引起皮脂溢性皮炎的原因。照此,伊维菌素的quleting与脱敏作用据信是抑制运动原的易变性,从而减少与疾病有关的毛细管应力。
发明人在Ormond Beach,Florida对大约100名患者进行历时大约七年的实验,发现上述方法的结果在各种顽固性皮脂溢性皮炎的治疗中是既安全又显著有效的。进而,在按照适当的方案对患者使用伊维菌素后,没有见到疾病的复发。而且,没有与现有技术药物治疗、特别是局部抗生素有关的副作用出现,例如变应性刺激作用或灼伤。从而在我使用上述伊维菌素洗剂和霜剂时,还没有遇到患者产生任何自体免疫应答,而这是利用抗生素治疗偶尔会遇到的情况,例如红霉素、四环素和咪唑类,如ketanazole。因此,我相信我已经发现了有效和几乎普遍安全的治疗皮脂溢性皮炎的方法,该方法可能在与皮脂溢性皮炎共有病因学类型的牛皮癣治疗中具有另外的价值。
尽管已经显示和描述了本发明优选的实施方式,不过不言而喻的是本发明可以体现为本文具体显示和描述以外的方式,并且在所述实施方式中,可以在部分内容的形式和排列上进行某些改变,而不背离本发明的基础构思或原理,后者阐明在随附的权利要求书中。
Claims (7)
1、皮脂溢性皮炎的治疗方法,包含下列步骤:
(a)使用有效量伊维菌素与水形成洗剂;
(b)每日向病变部位涂抹所述洗剂持续大约七天;和
(c)每月重复涂抹一至四次持续若干月。
2、如权利要求1所述方法,其中所述伊维菌素的治疗有效量包含至少750mcg/ml的浓度。
3、如权利要求2所述方法,其中该方法进一步包含下列步骤:
(d)在所述步骤(c)之后涂抹所述洗剂大约每月一次。
4、皮脂溢性皮炎的治疗方法,包含下列步骤:
(a)使用治疗有效量伊维菌素与药学上可接受的载体形成霜剂;
(b)每日向病变部位涂抹所述霜剂持续大约七天;和
(c)每月重复涂抹一至四次持续若干月。
5、如权利要求4所述方法,其中所述伊维菌素的治疗有效量在所述霜剂内包含至少750mcg/ml的浓度。
6、如权利要求5所述方法,其中所述药学上可接受的载体选自由丙二醇、月桂基硫酸钠、黄原胶及其组合组成的载体组。
7、如权利要求4所述方法,进一步包含下列步骤:
(d)在所述步骤(c)之后涂抹所述霜剂大约每月一次。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/605,747 US6319945B1 (en) | 2000-06-29 | 2000-06-29 | Method of treatment of seborrheic dermatitis |
US09/605,747 | 2000-06-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1383379A true CN1383379A (zh) | 2002-12-04 |
CN1171588C CN1171588C (zh) | 2004-10-20 |
Family
ID=24425042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018018572A Expired - Fee Related CN1171588C (zh) | 2000-06-29 | 2001-06-27 | 伊维菌素在制备用于治疗皮脂溢性皮炎的药物中的应用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6319945B1 (zh) |
EP (1) | EP1294375B1 (zh) |
JP (1) | JP3802485B2 (zh) |
CN (1) | CN1171588C (zh) |
AT (1) | ATE314068T1 (zh) |
AU (1) | AU2002216748A1 (zh) |
CA (1) | CA2384448C (zh) |
DE (1) | DE60116302T2 (zh) |
ES (1) | ES2252312T3 (zh) |
WO (1) | WO2002002056A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110604741A (zh) * | 2018-06-15 | 2019-12-24 | 瑞恩生化科技有限公司 | 抑制皮肤细胞增生的组合物及其应用 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897559B2 (en) * | 2000-06-29 | 2011-03-01 | Parks L Dean | Dermatological composition and kit containing avermectin compound for treating dermatological conditions |
US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
MXPA04012896A (es) | 2002-06-26 | 2005-03-31 | Avery Dennison Corp | Peliculas polimericas orientadas en la direccion de mecanizado y metodos de preparacion de las mismas. |
RU2350333C3 (ru) * | 2003-04-24 | 2018-08-24 | Галдерма С.А. | Применение ивермектина для лечения дерматологических расстройств |
FR2854074B1 (fr) | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
FR2867684B1 (fr) * | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
FR2894823B1 (fr) * | 2005-12-20 | 2008-02-29 | Galderma Sa | Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie |
BRPI0711963B1 (pt) | 2006-06-14 | 2019-09-17 | Avery Dennison Corporation | Etiquetas e rótulos conformáveis e destacáveis de orientação direcionada por máquina, e processos para preparação |
EP2035226A2 (en) | 2006-06-20 | 2009-03-18 | Avery Dennison Corporation | Multilayered polymeric film for hot melt adhesive labeling and label stock and label thereof |
EP2653160B1 (en) * | 2006-10-12 | 2017-09-27 | Topaz Pharmaceuticals Inc. | Topical ivermectin formulations and methods for elimination and prophylaxis of body lice |
US8901163B2 (en) | 2007-01-03 | 2014-12-02 | Galderma S.A. | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
EP2629772B1 (en) | 2010-10-20 | 2016-05-18 | Galderma S.A. | Ivermectin for use in the treatment of hemorrhoids |
US8901090B2 (en) | 2010-10-20 | 2014-12-02 | Galderma S.A. | Method of treating otitis externa using macrocyclic lactone compound |
US9233118B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
US9782425B2 (en) | 2013-07-08 | 2017-10-10 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
CN106794664B (zh) | 2014-06-02 | 2021-06-18 | 艾利丹尼森公司 | 耐磨强度、透明度和适形性增强的膜 |
EP4062907A1 (fr) | 2021-03-23 | 2022-09-28 | Substipharm | Formulation par voie orale d'ivermectine et utilisations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439924A (en) * | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
US5877295A (en) * | 1992-09-30 | 1999-03-02 | The Center For Blood Research | Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen |
DE4328689A1 (de) * | 1993-08-26 | 1995-03-02 | Beiersdorf Ag | Verfahren zur Detektion und Zählung von Mikroorganismen |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
KR100459747B1 (ko) * | 1996-05-20 | 2005-01-27 | 오쓰까 세이야꾸 가부시키가이샤 | 로제시아치료제 |
US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
KR100315465B1 (ko) * | 1998-11-23 | 2002-02-19 | 성재갑 | 수용성고분자와알코올을포함하는주사제용동물구충제조성물 |
-
2000
- 2000-06-29 US US09/605,747 patent/US6319945B1/en not_active Expired - Lifetime
-
2001
- 2001-06-27 AT AT01984091T patent/ATE314068T1/de not_active IP Right Cessation
- 2001-06-27 CN CNB018018572A patent/CN1171588C/zh not_active Expired - Fee Related
- 2001-06-27 JP JP2002506679A patent/JP3802485B2/ja not_active Expired - Fee Related
- 2001-06-27 ES ES01984091T patent/ES2252312T3/es not_active Expired - Lifetime
- 2001-06-27 DE DE60116302T patent/DE60116302T2/de not_active Expired - Lifetime
- 2001-06-27 AU AU2002216748A patent/AU2002216748A1/en not_active Abandoned
- 2001-06-27 EP EP01984091A patent/EP1294375B1/en not_active Expired - Lifetime
- 2001-06-27 CA CA002384448A patent/CA2384448C/en not_active Expired - Fee Related
- 2001-06-27 WO PCT/US2001/041159 patent/WO2002002056A2/en active IP Right Grant
- 2001-10-12 US US09/976,914 patent/US6433006B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110604741A (zh) * | 2018-06-15 | 2019-12-24 | 瑞恩生化科技有限公司 | 抑制皮肤细胞增生的组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US6319945B1 (en) | 2001-11-20 |
ES2252312T3 (es) | 2006-05-16 |
US6433006B2 (en) | 2002-08-13 |
US20020019354A1 (en) | 2002-02-14 |
CA2384448A1 (en) | 2002-01-10 |
CN1171588C (zh) | 2004-10-20 |
JP2004501939A (ja) | 2004-01-22 |
JP3802485B2 (ja) | 2006-07-26 |
DE60116302T2 (de) | 2006-08-10 |
ATE314068T1 (de) | 2006-01-15 |
WO2002002056A2 (en) | 2002-01-10 |
EP1294375A2 (en) | 2003-03-26 |
EP1294375A4 (en) | 2004-06-09 |
AU2002216748A1 (en) | 2002-01-14 |
CA2384448C (en) | 2008-09-16 |
WO2002002056A3 (en) | 2002-03-28 |
EP1294375B1 (en) | 2005-12-28 |
DE60116302D1 (de) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1171588C (zh) | 伊维菌素在制备用于治疗皮脂溢性皮炎的药物中的应用 | |
ES2264170T3 (es) | Utilizacion de complejos para la preparacion de composiciones para el tratamiento de pieles sensibles, procedimiento de preparacion y composiciones hipoalergenicas. | |
US6399651B1 (en) | Method of treating dermatoses using avermectin compound | |
EP1439832B1 (en) | Method of treating acne vulgaris using avermectin compound | |
CA2866527C (en) | Use of isoeugenol esters in treating hyperpigmentation | |
McGrath et al. | The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs | |
EP0988040B1 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
US20020037314A1 (en) | Compositions and methods | |
US7897559B2 (en) | Dermatological composition and kit containing avermectin compound for treating dermatological conditions | |
US4034114A (en) | Treatment of skin keratoses with retinal | |
ÖZTÜRK et al. | Pharmacological and pharmaceutical technological overview for seborrheic dermatitis: A review about topical application and new approaches | |
Eaglstein et al. | Topical corticosteroid therapy: Efficacy of frequent application | |
CN1748707A (zh) | 伊维菌素在脂溢性皮炎治疗中的治疗应用及应用方法 | |
CN114452292B (zh) | 白头翁皂苷b4在制备皮肤护理品中的应用 | |
Shelley et al. | Scrotal dermatitis caused by 5-fluorouracil (Efudex) | |
Guin | Treatment of acne vulgaris with topical clindamycin phosphate: a double‐blind study | |
CN112006988B (zh) | 医用皮肤修护喷剂在制备治疗皮炎药物中的应用 | |
Stankier | Diseases of the skin. Psoriasis. | |
Shenenberger | Curbing the psoriasis cascade: Therapies to minimize flares and frustration | |
CN102641283B (zh) | 一种治疗头屑的药物及其制备方法 | |
ES2645535T3 (es) | Composiciones tópicas para tratar trastornos, enfermedades y dolencias inflamatorios | |
CN114469969A (zh) | 白头翁皂苷b5在制备皮肤护理品中的应用 | |
Verbov | Eczema Herpeticum in a Man of 68 | |
Lin et al. | Medical and surgical treatment of the skin in epidermolysis bullosa | |
TRADE | llBRIllM' |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041020 Termination date: 20120627 |